Atenolol attenuates autonomic dysfunction of rat jejunum submitted to cold ischemic preservation.
In vitro studies have demonstrated that cold ischemic preservation (CIP) employed in small bowel transplantation produces loss of intestinal motility due to severe lesions of autonomic enteric nerves and that this autonomic dysfunction is attenuated by antioxidant agents. In this work, we investigated whether preservation with atenolol attenuated autonomic dysfunction of rat jejunum submitted to long-term CIP. Jejunal segments (2 cm) of Wistar rats (12 to 16 weeks old) were surgically isolated and preserved at 4 degrees C in Ringer's lactate solution without (-) or with (+) 1 mumol/L atenolol (AT). After preservation for 12 hours, AT+ and AT- preparations were mounted in parallel in isolated organ baths containing 10 mL Tyrode's solution at 37 degrees C for the study of neurogenic contractions evoked by electrical field stimulation (EFS; 10 to 30 Hz, 1-ms duration, 60 V) or by stimulation with nicotinic (nicotine, NIC) or muscarinic (carbachol, CCh) cholinoceptor agents as well as nicotine (hexamethonium, HEX) and muscarinic (atropine, ATR) antagonists. Contractions induced by EFS (30 Hz) were 46% higher in AT+ (0.38 +/- 0.02 g) than AT- (0.26 +/- 0.01 g), while contractions induced by NIC (1 mmol/L) were 84% higher in AT+ (0.46 +/- 0.03 g) than in AT- (0.25 +/- 0.02 g). In addition, contractions induced by CCh (1 mmol/L) were 34% higher in AT+ (0.87 +/- 0.06 g) than in AT- (0.65 +/- 0.08 g). EFS-, NIC-, and CCh-induced contractions were inhibited by pretreatment of jejunum with HEX or ATR (1 mumol/30 min), in AT+ and AT-. These results suggest that addition of atenolol in the preservation solution attenuated autonomic dysfunction of rat jejunum submitted to long-term CIP.
Taha
M O
MO
Department of Surgery, Federal University of São Paulo, Escola Paulista de Medicina, Rua Botucatu 740, CEP 04023-900 São Paulo-SP, Brazil. taha@uol.com.br
Fraga
M M
MM
Guimarães
F A
FA
Jurkiewicz
A
A
Caricati-Neto
A
A
D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D000818:Animals; D001262:Atenolol / Q000627:therapeutic use*; D001342:Autonomic Nervous System Diseases / Q000517:prevention & control*; D007583:Jejunum / Q000294:innervation*; D008297:Male; D023421:Models, Animal; D009926:Organ Preservation / Q000009:adverse effects / Q000379:methods*; D051381:Rats; D017208:Rats, Wistar
D000319:Adrenergic beta-Antagonists; D001262:Atenolol